HK Stock Market Move | Shenzhen Hepalink Pharmaceutical Group (09989) rises more than 3%, recently its subsidiary Innohep sodium injection was approved in Kenya.

Shenzhen Hepalink Pharmaceutical Group (09989) rose more than 3%, with a rise of over 14% in the morning session. As of the time of writing, it has risen 2.6% to HK$3.95, with a trading volume of HK$14.75 million. On the news front, according to a message from Shenzhen Hepalink Pharmaceutical Group's official WeChat account, recently, Shenzhen Hepalink Pharmaceutical Group announced that their fully-owned subsidiary, Tiandao Medicine, has received approval for their enoxaparin sodium injection, known as Clotex, in Kenya. The product has been approved for sale by the Pharmacy and Poisons Board (PPB) of Kenya, with a approved specification of 0.4ml:40mg. This marks the fourth country in Africa where Hepalink's enoxaparin sodium injection has been approved, bringing the total number of countries and regions where the product is approved to 80. By relying on a vertically integrated heparin industry chain, an international quality system, cross-border registration experience, and commercial operation capabilities, the group has established a systematic capability covering raw materials, formulations, quality, supply, and market services, providing sustained high-quality and stable product guarantees for different regional medical systems. Currently, Shenzhen Hepalink Pharmaceutical Group, with two major formulation production bases in Nanshan and Pingshan, Shenzhen, has achieved world-class scaled production capacity of 550 million syringes of enoxaparin sodium injection per year.